Efficacy of a High-intensity Physical Activity Program on Renal Function in High Risk Patients With Type 2 Diabetes

Type2 Diabetes Clinical Trial

— ACTIDIANE  

Official title:

Randomized Trial to Assess the Efficacy of a High-intensity Physical Activity Program on Renal Function Decline in High Risk Patients With Type 2 Diabetes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03184662
• Other study ID #: ACTIDIANE
• Status: Recruiting
• Phase: N/A
• Start date: February 12, 2018
• Est. completion date: December 31, 2023

Study information

• Verified date: January 2021
• Source: Poitiers University Hospital
• Contact: Samy Hadjadj
• Phone: 00 33 253 48 27 01
• Email: samy.hadjadj[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Type 2 diabetes is a chronic condition whose prevalence is increasing globally. Kidney disease is a key complication of diabetes and is among the most common cause of end-stage renal disease, requiring renal replacement therapy.

It has been shown that the trajectory of renal function (estimated glomerular filtration rate

• eGFR) is of great prognostic value for renal and cardiovascular endpoints in diabetic patients. However the clinical use of this prognostic marker is not associated to date with a clear therapeutic intervention, effective in patients with type 2 diabetes identified with this biomarker.

In France, type 2 diabetes patients have twice less physical activity than non-diabetic persons. Recently, it has been published that physical activity was associated with an improvement of renal risk in patients with type 2 diabetes, recruited from the LOOK-AHEAD study. It was demonstrated that high-intensity physical activity (HIPA) can have several additional advantages over moderate-intensity, on blood pressure improvement, and cardiovascular risk profile modification. In addition, this procedure was shown to be safe in patients with high cardiovascular risk.

We plan to perform a randomized intervention comparing a structured program of high-intensity physical activity (HIPA) vs standard recommendations for physical activity on renal function decline (primary outcome) and mortality, renal and cardiovascular endpoints, patients' safety and quality of life (secondary outcomes). Study participants will be patients with established type 2 diabetes and a high renal risk, identified by rapid renal function decline, defined as a eGFR slope below -5ml/min per 1.73 m2/yr. The intervention is planned to last for 2 years.

Description:

I- Visit organisation

V1 (screening) informed consent / examination / inclusion and non-inclusion criteria / medical history M/F LUTS / EPICES score / ECG Serum creatinine determination

V2 (Randomization) examination / verification of participation criteria / randomization Cystatin C collection / Biology Hypoglycemia notification / QAPPA / RPAQ / NAQA / Questionnaires (EQ-5D3L, SF12, Rosenberg Self esteem) / Accelerometer (ancillary) / Impedance-meter (ancillary) 6-minute step test / 10-meter walk test

V3 (1 month) examination / Hypoglycemia notification / QAPPA / RPAQ / Accelerometer (ancillary)

V4 (3 months) examination / Hypoglycemia notification / QAPPA / RPAQ / Questionnaires (EQ-5D3L, SF12, Rosenberg Self esteem) / Accelerometer (ancillary) 6-minute step test Biology

V5 (6 months) examination / Hypoglycemia notification / QAPPA / RPAQ / Questionnaires(EQ-5D3L, SF12, Rosenberg Self esteem) / Accelerometer (ancillary) 6-minute step test Cystatin C collection / Biology

V6 (12 months) examination / Hypoglycemia notification / QAPPA / RPAQ / NAQA / M/F LUTS / Questionnaires(EQ-5D3L, SF12, Rosenberg Self esteem) / ECG /Accelerometer (ancillary) / Impedance-meter (ancillary) Cystatin C collection / Biology 6-minute step test / 10-meter walk test

V7 (18 months) examination / Hypoglycemia notification / QAPPA / RPAQ / Questionnaires(EQ-5D3L, SF12, Rosenberg Self esteem) / Accelerometer (ancillary) Cystatin C collection / Biology 6-minute step test

V8 (24 months) / premature discontinuation examination / Hypoglycemia notification / QAPPA / RPAQ / NAQA / M/F LUTS / Questionnaires (EQ-5D3L, SF12, Rosenberg Self esteem) / ECG / Accelerometer (ancillary) / Impedance-meter (ancillary) 6-minute step test / 10-meter walk test Cystatin C collection / Biology

II- Recruitment criteria Inclusion

• Age : 45 and higher

• Female or male

• Type 2 diabetes with diabetes typing according to widely-accepted clinical and biological criteria [3].

• Subject able to practice physical activity. This includes a normal exercise test with or without anti-ischemic drugs, performed in the preceding 6 months or short before randomization. A certificate of no contre-indication for PA is to be delivered prior to randomization.

• With at least 3 available creatinine measurements in the 6 to 24 preceding months showing a rapid renal function decline defined as an eGFR slope below -5 ml/min/yr

• Estimated GFR equal to or higher than 30 ml/min/1.73m², defined by the CKD-EPI formula, at inclusion visit

Non inclusion

• Age strictly lower than 45 years

• Indication for cardiovascular rehabilitation (notably patient with ischemic heart disease or coronary revascularisation)

• Treatment with systemic NSAIDs or corticosteroids

• Lower limb amputation (above trans-metacarpal)

• Active proliferative retinopathy (risk of bleeding in case of effort)

• Contra-indication for the participation to PA:

• Severe non-operated valvulopathy

• Uncontrolled hypertension > 180/110 mmHg

• Thrombus in the left ventricular cavity

• Unstable coronaropathy, according to physician

• NYHA stage IV heart failure

• Any condition that would jeopardize patient's safety or would affect the conduct of the study

• Pregnant or breast-feeding women or women of child-bearing potential without effective contraception during the study

• Any situation associated with unreliable cystatin-C determinations, according to patient medical history: HIV positivity, melanoma and thyroid dysfunction

• Simultaneous participation to any interventional study able to interfere with the current study endpoints

• Patients not registered to the social security

• Protected adults (under guardianship and trusteeship)

• Subject unable to express their consent (due to intellectual/mental incapacity)

III- Intervention HIPA group Twice weekly physical activity session in a dedicated structure, supervised by a graduated coach, alternating sessions of strengthening and intermittent HIPA, allowing a mixed stimulation of neuro-muscular and cardiovascular systems, and regular (every 3 months) adjustment of the intensity of the program.

Control group Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD (French Language Diabetes Society) supported by patient's oriented leaflet.

IV- Handling with the COVID-19 pandemics

The COVID-19 pandemics has modified the shape of the study with

• difficulties to comply with the study plan, including recruitment pace. Visits can be postponed if required but investigators are encouraged to follow the initial plan. The time between randomization and V3 (1 month) and V4 (3 months) can sometimes be too short and it is acceptable to perform this visit by phone or even to cancel it.

• difficulties to comply with physical activity (PA) plan. As PA facilities have been locked down in the pandemics context, the sports committee of the ACTIDIANE study has agreed to move attendances to the gym to some remote PA sessions, via websession or if not possible, via telephone coaching sessions.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: December 31, 2023
• Est. primary completion date: September 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 45 Years and older

Eligibility

Inclusion Criteria:

• Type 2 diabetes

• Rapid renal decline function (yearly loss of eGFR over -5ml/min/1.73 m2) in the 6 to 24 preceding months

Exclusion Criteria:

• Lower limb amputation

• Indication for rehabilitation program

• Contra-indication for physical activity

• Unstable angina, left atrial thrombus,

• Unstable thyroid function

• Corticosteroids treatment

• Long-term NSAIDs

• Simultaneous participation to any interventional study able to interfere with the current study endpoints

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Diabetic Kidney Disease
• Diabetic Nephropathies
• Kidney Diseases
• Type2 Diabetes

Intervention

Other:
• HIPA
inclusion in a program with 2 weekly sessions of structured physical activity of 1 hour in a dedicated structure, under the supervision of a graduated coach. First 3 months : physical reconditioning 3 months and after: alternating sessions of physical strengthening and intermittent high-intensity physical activity Adaptation of the intensity of the program according to evaluation tests every 3 months
• Counseling PA
Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD

Locations

Country	Name	City	State
Belgium	Hospital of Liège	Liège
France	Besançon Hospital	Besançon
France	Bordeaux University Hospital	Bordeaux
France	Caen University Hospital	Caen
France	CH Chartres	Chartres
France	Clermont Ferrand University Hospital	Clermont Ferrand
France	CHG Sud Francilien	Corbeil-Essonnes
France	CHU Dijon	Dijon
France	CHU Lille	Lille
France	Chu de Lyon	Lyon
France	CHRU	Montpellier
France	CHU Nancy	Nancy
France	Chu de Nice	Nice
France	Bichat University Hospital	Paris
France	Hôpital Pitié Salpétrière	Paris
France	La Riboisière Hospital	Paris
France	Poitiers University Hospital	Poitiers
France	CHU Strasbourg	Strasbourg
France	CHU Toulouse	Toulouse
France	CHU de TOURS	Tours

Sponsors (21)

Lead Sponsor

Collaborator

Poitiers University Hospital

Bichat Hospital, Central Hospital, Nancy, France, Centre Hospitalier Sud Francilien, Centre Hospitalier Universitaire de Besancon, Centre Hospitalier Universitaire de Nice, Centre Hospitalier Universitaire Dijon, Groupe Hospitalier Pitie-Salpetriere, Hopital Lariboisière, Hospices Civils de Lyon, HOSPITAL, CHARTRES, Nantes University Hospital, University Hospital, Bordeaux, University Hospital, Caen, University Hospital, Clermont-Ferrand, University Hospital, Lille, University Hospital, Montpellier, University Hospital, Strasbourg, University Hospital, Toulouse, University Hospital, Tours, University of Liege

Countries where clinical trial is conducted

Belgium,  France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Renal Function Decline	Estimated glomerular filtration rate slope computed within 2 years, evaluated with the cystatin-derived CKD-EPI formula At least 3 available determinations of estimated glomerular filtration rate will be required to perform the calculation of the slope	2 years
Secondary	Incidence of ESRF	Incidence of end-stage renal failure requiring renal replacement therapy	2 years
Secondary	Number of patients with a decrease in eGRF	Number of patients with a decrease in eGRF greater than 40% of baseline value	2 years
Secondary	All cause death	Number of patients who died during the study (all cause)	2 years
Secondary	Cardiovascular death	Cardiovascular death as proposed by the ICD-10 classification	2 years
Secondary	Renal death	Renal death as defined as a situation where renal replacement therapy could be used but was not applied	2 years
Secondary	MACE	MACE : major adverse cardiovascular endpoints : first occuring among cardiovascular death, myocardial infarction and stroke	2 years
Secondary	Severe congestive heart failure	Severe congestive heart failure requiring hospitalization, adjudicated by a study outcome committee	2 years
Secondary	Coronary artery disease	Coronary artery disease : myocardial infarction and/or coronary artery revascularizaton	2 years
Secondary	Quality of life EQ-5D3L	Quality of life : assessed by using EQ-5D3L questionnaire	2 years
Secondary	Male/Female lower urinary tract symptoms (LUTS)	Male/Female lower urinary tract symptoms : assessed by using M/F LUTS questionnaire	2 years
Secondary	Safety of the intervention	including : adverse events, foot ulceration requiring medical advise, musculoskeletal disorders, hypoglycemia	2 years
Secondary	Quality of life SF12	Quality of life : assessed by using SF12 questionnaire	2 years
Secondary	Safety of HIPA performed by e-coaching in the context of COVID infection	AE and SAE will be carefully reviewed to assess if the HIPA sessions are safe as performed with e-coaching/ telephone-coaching during lock-down due to the COVID-19 pandemics	2 years